Evidence map›Paper›PMID 34393139›Full record

ArticleJournal of atherosclerosis and thrombosis2022

Evaluation of Workflow Delays in Stroke Reperfusion Therapy: A Comparison between the Year-Long Pre-COVID-19 Period and the with-COVID-19 Period.

Takeshi Yoshimoto, Masayuki Shiozawa, Junpei Koge, Manabu Inoue, Masatoshi Koga, Masafumi Ihara, Kazunori Toyoda

Registry-linked trialOpen access · diamondAbstract readComparative Study
In one paragraph

Article in Journal of atherosclerosis and thrombosis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02251665 (National Cerebral and Cardiovascular Center), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02251665 active not recruitingnot on this map

National Cerebral and Cardiovascular Center (NCVC) Stroke Registry

TypeobservationalSponsorNational Cerebral and Cardiovascular Center, JapanRan2016 to 2028Enrolled5,374ConditionsStroke, AcuteArmsNo intervention
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Takeshi YoshimotoDepartment of Neurology, National Cerebral and Cardiovascular Center.
Masayuki ShiozawaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.
Junpei KogeDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.
Manabu InoueDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.
Masatoshi KogaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.
Masafumi IharaDepartment of Neurology, National Cerebral and Cardiovascular Center.
Kazunori ToyodaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center.
National Cerebral and Cardiovascular Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimWe evaluated the delay in stroke reperfusion therapy between the pre-coronavirus disease 2019 (COVID-19) period and the with-COVID-19 period, and compared this delay between each phase of the with-COVID-19 period.

methodsPatients with acute ischemic stroke (AIS) undergoing intravenous thrombolysis and/or mechanical thrombectomy were selected from our single-center prospective registry. The time to perform reperfusion therapy were compared between patients admitted from March 2019 to February 2020 (pre-COVID-19 group) and those from March 2020 to February 2021 (with-COVID-19 group). Patients in the with-COVID-19 group were further divided into three 4-month-long subgroups (first-phase: March to June 2020; second-phase: July to October 2020; third-phase: November 2020 to February 2021), and the time delay of reperfusion therapy were compared between these subgroups.

resultsOf 1,260 patients with AIS hospitalized in the study period, 265 patients were examined. Compared with the pre-COVID-19 group (133 patients; median age, 79 years), the with-COVID-19 group (132 patients; median age, 79 years) had a longer median door-to-imaging time (25 min vs. 27 min, P=0.04), and a longer door-to-groin puncture time (65 min vs. 72 min, P=0.02). In the three 4-month-long subgroups, the median door-to-needle time (49 min, 43 min, and 38 min, respectively; P=0.04) and door-to-groin puncture time (83 min, 70 min, and 61 min, P<0.01, respectively) decreased significantly during the with-COVID-19 period.

conclusionsThe delay in reperfusion therapy increased during the with-COVID-19 period compared with the pre-COVID-19 period. However, the door-to-needle time and door-to-groin puncture time decreased as time elapsed during the with-COVID-19 period. CLINICALTRIALS: gov Identifier: NCT02251665.

Indexed as

COVID-19Ischemic StrokeStrokeAgedHumansReperfusionThrombectomyThrombolytic TherapyTime-to-TreatmentWorkflowCoronavirus disease 2019Ischemic strokeReperfusion therapyWorkflow

Identifiers

PMID34393139
PMCPMC9252617
OpenAlexW3194504013

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.